Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

biovaluable Feb. 19 at 9:02 AM

$BCAB Short's attacks will continue today. But if you look at the gap in asking prices, Short sellers look easy to sell, but very hard to buy for repay. Until March 4th, whatever mischief the shorts are playing, shareholders have to hang in there.

1 · Reply

biovaluable Feb. 19 at 2:36 AM

$BCAB The merger of the subsidiary will be completed safely if it lasts until early March, and an additional $35M investment will flow from GATC. The current market capitalization is $10M, and more than three times the market capitalization of cash enters the company through the subsidiary. Since the SPV corporation does not have its own clinical performance cap, it has to pay the parent company BioAtla, and BioAtla can use the money paid to operate the company and develop assets such as epcam cd3.

0 · Reply

biovaluable Feb. 18 at 3:17 PM

$BCAB & short is out of borrow stock. Keep the position until 26.3.4. After the merger of subsidiaries is over, Short can't be paid back. Because stocks are down.

0 · Reply

biovaluable Feb. 18 at 3:14 PM

$BCAB Acorn, Millennium is either.

0 · Reply

biovaluable Feb. 18 at 3:13 PM

$BCAB Marshall wace llc with bullish at 25 4q. UK money associated with Lloyd insurance!

0 · Reply

biovaluable Feb. 18 at 3:09 PM

$BCAB more short! Add 20k at 0.1334 on my first buying point.

0 · Reply

whateverhappenedthere Feb. 18 at 3:02 PM

$BCAB are employees leaving yet? LinkedIn usually has the early tea

0 · Reply

BullRiderSC Feb. 18 at 2:29 PM

$BCAB

0 · Reply

biovaluable Feb. 18 at 3:37 AM

$BCAB I think this game will be fun. GATC has famous former officials who worked in academia and key government positions, and is preparing to go public with its new AI drug program Operon-DerisQ. First launched in October last year, CABROR2 ADC (cancer + anti-aging) is the first asset that will be released to the world. If this investment fails, the prospects for GATC's listing will also be dimmed. After March 4th, interesting things will happen!

0 · Reply

biovaluable Feb. 18 at 3:34 AM

$BCAB SPV established exclusively for CAB ROR2 ADC research will be in the form of direct insurance, and investors will have to go through Lloyds Insurance to make the investment with maximum principal coverage. This will be an innovation in clinical financing. In addition, if this inflow of investment is loaned or paid back to BioAtla (which owns 65% of the SPV) through SPV, research and negotiations on epcam, axl, CTLA4 assets, etc. can continue without additional capital increase.

1 · Reply

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Nov 21, 2025, 12:25 AM EST - 3 months ago

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 6:51 PM EST - 3 months ago

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 3 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 3 months ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 3 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 4 months ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 4 months ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 4 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 5 months ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 9, 2025, 2:43 AM EDT - 6 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 7 months ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 7 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 8 months ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 9 months ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 5:55 PM EDT - 10 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 10 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 10 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 10 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 10 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 10 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 6:18 PM EDT - 11 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 5:05 PM EDT - 11 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 11 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 1 year ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 1 year ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 1 year ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 1 year ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 2 years ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 2 years ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

biovaluable Feb. 19 at 9:02 AM

1 · Reply

biovaluable Feb. 19 at 2:36 AM

0 · Reply

biovaluable Feb. 18 at 3:17 PM

$BCAB & short is out of borrow stock. Keep the position until 26.3.4. After the merger of subsidiaries is over, Short can't be paid back. Because stocks are down.

0 · Reply

biovaluable Feb. 18 at 3:14 PM

$BCAB Acorn, Millennium is either.

0 · Reply

biovaluable Feb. 18 at 3:13 PM

$BCAB Marshall wace llc with bullish at 25 4q. UK money associated with Lloyd insurance!

0 · Reply

biovaluable Feb. 18 at 3:09 PM

$BCAB more short! Add 20k at 0.1334 on my first buying point.

0 · Reply

whateverhappenedthere Feb. 18 at 3:02 PM

$BCAB are employees leaving yet? LinkedIn usually has the early tea

0 · Reply

BullRiderSC Feb. 18 at 2:29 PM

$BCAB

0 · Reply

biovaluable Feb. 18 at 3:37 AM

0 · Reply

biovaluable Feb. 18 at 3:34 AM

1 · Reply

biovaluable Feb. 18 at 3:34 AM

$BCAB Also, considering that no clinical studies have been resigned or suspended so far, the company's funds seem to be running very tight. Including the $5M investment inflow from AIRC in January. The $35M funding in the first quarter is also expected to flow in once the subsidiary reverse merger process is completed. And this will serve as a premium to buy Lloyds Syndicate 1966 clinical fund insurance, rather than the total investment. Considering that conventionally the premium rate for clinical fund insurance is around 20-30%, I think the clinical fund available through Lloyds will be over $100 million.

0 · Reply

biovaluable Feb. 18 at 3:28 AM

$BCAB It will also likely have to file a lawsuit with the Nasdaq Listing Commission, which has ruined $1 retention requirements and cancer research for the company through an unreasonable delisting notice despite meeting MVLS requirements last year.

0 · Reply

biovaluable Feb. 18 at 3:26 AM

$BCAB Marshall and Lloyds are some of the best investors and insurance management companies in the UK. Jay Short was probably thinking of insurance-backed clinical financing (Syndgate 1966). This makes sense to everything from GATC(DerisQ), Marshall, Lloyds(insurance), Inversagen ai llc wtih Saudi Neom biotech investing. There would have been only one requirement for them to keep the Nasdaq listed. So, if the reverse merger succeeds on March 4th, everything will turn around dramatically. I think the market will have a big stomachache when the insurance-backed clinical funding is successfully raised without dilution, and then epcam data is released. So until then, enjoy it short seller! I'm going to start slowly collecting it from now on. I wonder if there will be stocks on the market that can cover as much as the short positions they've built.

0 · Reply

biovaluable Feb. 18 at 1:03 AM

$BCAB Marshall, Acorn, Millennium is still here.

0 · Reply

biovaluable Feb. 18 at 1:02 AM

$BCAB more short. Either long or short will go bankrupt.The current market cap is below $10M. Enjoy it. I believe Jay & ror2 adc via GATC&Lloyds & epcam cd3 P1 data. And ncetin4 tce milestone to be paid by CNTX soon. Enjoy it until reverse merger of subsidiaries, dirty shorters! MARSHALL WACE LLP Bought Over 800,000 Shares In Q4. What it means? British investor and insurers.

0 · Reply

BullRiderSC Feb. 17 at 9:29 PM

$BCAB

0 · Reply

LabPsycho Feb. 17 at 2:46 PM

$BCAB @dudereally exactly...same argument can be made for many biotechs...why would a big pharma company do a deal with them with significant upfront when they could buy the company for less. This is the death spiral I alluded to over 2 yr ago...and other things. Go back and read through all my posts...the cue were there years ago and I posted my opinion. Once these things get below 5 ish...thats usually it with a few exceptions.

1 · Reply

BillionerOfKing Feb. 17 at 1:55 PM

$BCAB Current Stock Price: $0.15 Contracts to trade: $0.5 BCAB Feb 20 2026 Call Entry: $0.05 Exit: $0.08 ROI: 84% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

LongerThanLong Feb. 17 at 1:36 PM

$BCAB why do I own 0.1% of this company... seems like a stupid decision but hey maybe one day I will make a profit on this gamble :D

0 · Reply

LabPsycho Feb. 16 at 8:54 PM

$BCAB Ugh! I do not think there is a single person here, or anywhere, including me, of WTF is going on with this company: Merger? Current Cash? R/S? Reverse merger? Delisting? $CNTX relationship / milestones? A.I.? (oh now BCAB wants to do this when I offered this idea and guidance years ago!). Can anyone post a clear / tenable set of bullet points of possible outcomes.

1 · Reply

jackabe Feb. 13 at 8:47 PM

$BCAB well.that fared well

1 · Reply

olecavi Feb. 13 at 7:18 PM

$BCAB whats the purpose of the proposed merger? They are still aiming to do the reverse stock split. With the merger a new company will be formed and with that maybe new retail investors. But the outcome will be the same, in the long term they will keep driving the stock price down.

1 · Reply

Market Cap	8.96M
Revenue (ttm)	11.00M
Net Income (ttm)	-69.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.36%
Debt to Equity Ratio	0.00

Volume	2,604,100
Avg Vol	2,500,890
Day's Range	N/A - N/A
Shares Out	63.46M
Stochastic %K	12%
Beta	1.10
Analysts	Sell
Price Target	$10.00